AU2001267058A1 - Aav vector-based compositions and therapeutic uses thereof - Google Patents

Aav vector-based compositions and therapeutic uses thereof

Info

Publication number
AU2001267058A1
AU2001267058A1 AU2001267058A AU6705801A AU2001267058A1 AU 2001267058 A1 AU2001267058 A1 AU 2001267058A1 AU 2001267058 A AU2001267058 A AU 2001267058A AU 6705801 A AU6705801 A AU 6705801A AU 2001267058 A1 AU2001267058 A1 AU 2001267058A1
Authority
AU
Australia
Prior art keywords
vector
raav
cytokine
gene
leptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001267058A
Other languages
English (en)
Inventor
William W. Hauswirth
Pushpa S. Kalra
Satya P. Kalra
Lyle L. Moldawer
Nicholas Muzyczka
Sergei Zolotukhin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of AU2001267058A1 publication Critical patent/AU2001267058A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001267058A 2000-06-09 2001-06-08 Aav vector-based compositions and therapeutic uses thereof Abandoned AU2001267058A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59081000A 2000-06-09 2000-06-09
US09590810 2000-06-09
PCT/US2001/040901 WO2001094605A2 (fr) 2000-06-09 2001-06-08 Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques

Publications (1)

Publication Number Publication Date
AU2001267058A1 true AU2001267058A1 (en) 2001-12-17

Family

ID=24363808

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001267058A Abandoned AU2001267058A1 (en) 2000-06-09 2001-06-08 Aav vector-based compositions and therapeutic uses thereof

Country Status (4)

Country Link
EP (1) EP1290206A2 (fr)
AU (1) AU2001267058A1 (fr)
CA (1) CA2410512A1 (fr)
WO (1) WO2001094605A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1498964A (zh) * 2002-11-07 2004-05-26 本元正阳基因技术股份有限公司 可诱导RNAi途径的用于基因治疗的系列重组腺相关病毒
GB0327384D0 (en) * 2003-11-25 2003-12-31 Queen Mary & Westfield College Gene therapy
WO2006069907A1 (fr) * 2004-12-28 2006-07-06 Ares Trading S.A. Compositions et procedes de traitement de la schizophrenie et de troubles associes
US7662298B2 (en) * 2005-03-04 2010-02-16 Northwestern University Separation of carbon nanotubes in density gradients
EP2059479B1 (fr) 2006-08-30 2017-11-15 Northwestern University Populations de nanotubes de carbone à paroi unique monodispersées, et procédés de fabrication associés
CA2704418A1 (fr) * 2007-10-30 2009-05-07 Neurologix, Inc. Nouvelle methode de therapie genique concernant le traitement de l'obesite liee a des troubles du metabolisme
WO2012030625A1 (fr) 2010-08-31 2012-03-08 Cornell University Prothèse rétinienne
EP3088044B1 (fr) 2010-02-26 2020-04-08 Cornell University Prothèse de rétine
CA2805170C (fr) 2010-07-12 2021-09-21 Fatima Bosch Tubert Composition de therapie genique destinee a etre utilisee dans le traitement du diabete
US9302103B1 (en) 2010-09-10 2016-04-05 Cornell University Neurological prosthesis
CN103890781B (zh) 2011-08-25 2017-11-21 康奈尔大学 用于机器视觉的视网膜编码器
EP2692868A1 (fr) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Vecteurs viraux adéno-associés (AAV) utiles pour la transduction de tissu adipeux
US10973931B2 (en) 2014-09-16 2021-04-13 Universitat Autònoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
ES2900973T3 (es) 2015-01-07 2022-03-21 UNIV AUTòNOMA DE BARCELONA Constructo genético de vector individual que comprende genes de insulina y glucoquinasa
CN112842690B (zh) 2015-04-20 2023-10-17 康奈尔大学 具有维度数据缩减的机器视觉
WO2017060510A1 (fr) * 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de la maladie d'alzheimer
EP3436078B1 (fr) * 2016-03-31 2021-10-27 University of Cincinnati Méthodes et compositions pour le traitement de la sla
RU2653487C1 (ru) * 2016-11-30 2018-05-08 Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена lif и/или уменьшением количества белка фактора, ингибирующего лейкемию, на основе генно-терапевтических субстанций с геном lif, способ получения и использования
WO2020023621A1 (fr) * 2018-07-24 2020-01-30 Puneeth Iyengar Traitement amélioré de perte de poids
RU2720376C1 (ru) * 2018-11-29 2020-04-29 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов IL11, LIF, DICER, HOXA10, WT1, для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-IL11, или Escherichia coli SCS110-AF/VTvaf17-LIF, или Escherichia coli SCS110-AF/VTvaf17-DICER, или Escherichia coli SCS110-AF/VTvaf17-HOXA10, или Escherichia coli SCS110-AF/VTvaf17-WT1, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
RU2715314C1 (ru) * 2019-01-25 2020-02-26 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор VTvaf17-Act1-Cas9 на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген Cas9, для гетерологичной экспрессии этого целевого гена в клетках растений при геномном редактировании растений, способ получения и применения генотерапевтического ДНК-вектора, штамм Escherichia coli SCS110-AF/VTvaf17-Act1-Cas9, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
GB202202628D0 (en) * 2022-02-25 2022-04-13 Babraham Inst Novel use and method comprising IL-2 and a tissue- or organic-specific targeting moiety

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514904A (ja) * 1996-06-20 2002-05-21 メルク エンド カンパニー インコーポレーテッド 肥満に対する遺伝子治療
JP2001500376A (ja) * 1996-09-06 2001-01-16 カイロン コーポレイション 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
IT1288388B1 (it) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
WO1999006562A1 (fr) * 1997-07-31 1999-02-11 Chiron Corporation Procede permettant de readministrer un vecteur viral adeno-associe via l'immunodepression de l'hote
CA2324225A1 (fr) * 1998-03-20 1999-09-23 The Trustees Of The University Of Pennsylvania Compositions et methodes de production de virus adeno-associes recombines sans auxiliaire

Also Published As

Publication number Publication date
EP1290206A2 (fr) 2003-03-12
CA2410512A1 (fr) 2001-12-13
WO2001094605A2 (fr) 2001-12-13
WO2001094605A3 (fr) 2002-12-05

Similar Documents

Publication Publication Date Title
AU2001267058A1 (en) Aav vector-based compositions and therapeutic uses thereof
US9023617B2 (en) Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
US20060078542A1 (en) Gel-based delivery of recombinant adeno-associated virus vectors
US20060248604A1 (en) Adeno-associated virus-delivered ribozyme compositions and methods of use
US20150005369A1 (en) Methods of gene delivery using capsid-modified raav expression systems
JP2006523227A (ja) Ｍｄａ−７を含む方法および組成物
US20150045416A1 (en) Methods and Compositions for Gene Delivery
US20050271625A1 (en) RAAV-neprilysin compositions and methods of use
US6696415B2 (en) Treatment of ocular neovascularization and related diseases
WO2000069454A1 (fr) Suppression de l'igfbp-2 endogene visant a inhiber le cancer
US20060281703A1 (en) Treatment of disease using an improved regulated expression system
CN116685329A (zh) 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
US11510999B2 (en) Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
Ikeda et al. Recombinant Sendai virus-mediated gene transfer into adult rat retinal tissue: efficient gene transfer by brief exposure
US6534310B1 (en) Suppression of proteolytic activity by dysfunctional protease formation
WO2005014775A2 (fr) Compositions de raav et methodes d'administration de polypeptides du facteur vii humain et de traitement de l'hemophilie a
US20090068147A1 (en) Raav vector-based pro-opiomelanocortin compositions and methods of use
WO1996014863A9 (fr) Suppression de l'activite proteolytique par formation de protease dysfonctionnelle
US20060292609A1 (en) Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
EP2137314B1 (fr) Nouvelles molécules modulatrices destinées à un système d'expression régulée amélioré
Flannery et al. Ribozyme-mediated gene therapy for autosomal dominant retinal degeneration
US20080076729A1 (en) Interferon-beta gene therapy using an improved, regulated expression system
EP0963440A1 (fr) Methodes ameliorees de transduction cellulaire
WO1998022605A9 (fr) Methodes ameliorees de transduction cellulaire